BMO Capital flags REITs risk from FMAP funding changes
BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal Medical ...
BMO Capital maintains Outperform on Beam Therapeutics stock
BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...
Q32 Bio downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $3, down from $22. The company announced an ...
Fluence Energy downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Fluence Energy (FLNC) to Market Perform from Outperform with a price target of $10, down from $22. The company’s Q1 ...